541 related articles for article (PubMed ID: 19190817)
1. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
Hammerstingl C; Omran H; Tripp C; Poetzsch B
Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
[TBL] [Abstract][Full Text] [Related]
2. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
3. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
[TBL] [Abstract][Full Text] [Related]
4. [Perioperative Bridging with Enoxaparin. Results of the Prospective BRAVE Registry with 779 Patients].
Omran H; Hammerstingl C; Paar WD;
Med Klin (Munich); 2007 Oct; 102(10):809-15. PubMed ID: 17928964
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
[TBL] [Abstract][Full Text] [Related]
6. Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures.
Hammerstingl C; Omran H;
Thromb Haemost; 2009 Jun; 101(6):1085-90. PubMed ID: 19492151
[TBL] [Abstract][Full Text] [Related]
7. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery.
Douketis JD; Woods K; Foster GA; Crowther MA
Thromb Haemost; 2005 Sep; 94(3):528-31. PubMed ID: 16268467
[TBL] [Abstract][Full Text] [Related]
8. Bridging with enoxaparin using a half-therapeutic dose regimen: safety and efficacy.
Klamroth R; Gottstein S; Essers E; Landgraf H
Vasa; 2010 Aug; 39(3):243-8. PubMed ID: 20737383
[TBL] [Abstract][Full Text] [Related]
9. Dosing and monitoring of enoxaparin (Low molecular weight heparin) therapy in children.
Ignjatovic V; Najid S; Newall F; Summerhayes R; Monagle P
Br J Haematol; 2010 Jun; 149(5):734-8. PubMed ID: 20346012
[TBL] [Abstract][Full Text] [Related]
10. Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.
Bui HT; Krisnaswami A; Le CU; Chan J; Shenoy BN
Am J Cardiol; 2009 Nov; 104(10):1429-33. PubMed ID: 19892063
[TBL] [Abstract][Full Text] [Related]
11. Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin.
Ramos-Esquivel A; Salazar-Sánchez L
Thromb Res; 2013 Oct; 132(4):433-6. PubMed ID: 24050826
[TBL] [Abstract][Full Text] [Related]
12. Perioperative bridging of chronic oral anticoagulation in patients undergoing pacemaker implantation--a study in 200 patients.
Hammerstingl C; Omran H
Europace; 2011 Sep; 13(9):1304-10. PubMed ID: 21508005
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients.
Vincent PD; Albert M; Champagne MC; Zikos T; Boulanger I; Blais L; Williamson DR
J Crit Care; 2011 Aug; 26(4):347-51. PubMed ID: 21454037
[TBL] [Abstract][Full Text] [Related]
14. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.
Barrett YC; Wang J; Song Y; Pursley J; Wastall P; Wright R; Lacreta F; Frost C
Thromb Haemost; 2012 May; 107(5):916-24. PubMed ID: 22398784
[TBL] [Abstract][Full Text] [Related]
15. Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety.
Kane-Gill SL; Feng Y; Bobek MB; Bies RR; Pruchnicki MC; Dasta JF
J Clin Pharm Ther; 2005 Jun; 30(3):207-13. PubMed ID: 15896237
[TBL] [Abstract][Full Text] [Related]
16. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
Zalc S; Lemos PA; Esteves A; Ribeiro EE; Horta P; Nicolau JC; Ramires JA; Cohen M; Martinez EE
J Invasive Cardiol; 2006 Feb; 18(2):45-8. PubMed ID: 16446514
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
Michaels LA; Gurian M; Hegyi T; Drachtman RA
Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
[TBL] [Abstract][Full Text] [Related]
18. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
Ma JM; Jackevicius CA; Yeo E
Ann Pharmacother; 2004 Oct; 38(10):1576-81. PubMed ID: 15328396
[TBL] [Abstract][Full Text] [Related]
19. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
